Toggle menu

Garfield-VTE Study

Start date:
May 2015
End date:
December 2019
Co-ordinated by:
Thrombosis Research Institute UK
Main trial site:
RIE

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world.

Aim

The study objectives are to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting.

Trial Design

Global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts.

In order to observe temporal trends in management of VTE a minimum of 2 cohorts will be recruited. Recruitment into the second (or subsequent cohorts) will commence when recruitment is completed into the first or previous cohort. It is estimated that each cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis.

Cohort One

5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months

Cohort Two

A further 5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months

Eligibility criteria

Inclusion Criteria

  1. Written informed consent
  2. Age 18 years and over
  3. Treated first time or recurrent DVT (lower or upper extremity), PE alone or overlapping DVT and PE confirmed by appropriate diagnostic methods (patients must be assessed for eligibility within 30 days of diagnosis)
  4. Patients included with recurrent VTE must have completed treatment for the previous VTE episode

Exclusion Criteria

  1. Patients for whom long-term follow up is not envisaged within the enrolling hospital or the associated primary care physician
  2. Patients participating in an interventional study that dictates treatments, visit frequency, or diagnostic procedures
  3. Patients with only superficial vein thrombosis (SVT)

Local PI

Dr Ann Lockman

Consultant in Acute Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study